Dataset

Identification of Multiple Sclerosis genetic markers leading to clinical benefits to affected patients [dataset]

BOND University
Don Staines (Aggregated by) Ekua Brenu (Aggregated by) Lotti Tajouri (Aggregated by) Sonya Marshall (Aggregated by)
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.4225/57/58b60c886ce94&rft.title=Identification of Multiple Sclerosis genetic markers leading to clinical benefits to affected patients [dataset]&rft.identifier=https://epublications.bond.edu.au/data/27&rft.publisher=BOND University&rft.description= Multiple Sclerosis (MS) is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed. Data in SPSS software. Associated publications: Immunomodulators as therapeutic strategies for managing Multiple Sclerosis &rft.creator=Ekua Brenu&rft.creator=Sonya Marshall&rft.creator=Don Staines&rft.creator=Lotti Tajouri&rft.date=2017&rft_rights=Contact Lotti_Tajouri@bond.edu.au to determine access conditions.&rft_subject=Multiple Sclerosis&rft_subject=Immunotherapy&rft_subject=Immune System&rft.type=dataset&rft.language=English Access the data

Licence & Rights:

view details

Contact Lotti_Tajouri@bond.edu.au to determine access conditions.

Access:

Other

Full description

Multiple Sclerosis (MS) is characterized by severe compromises to neuroimmune processes involving changes in immune cell function, soluble proteins and modulation of inflammatory processes. The introduction of therapeutic agents in the form of immunomodulators; interferon, phosphodiesterase inhibitors and Glatiramer acetate have proven to be useful to some extent in reducing the severity of MS. Herein the implications and effects of these molecules on the immune system in MS are reviewed. Additionally, the available evidence on the mode of action of neuropeptides in MS, their effectiveness on clinical measures, and current knowledge are also reviewed.

Data in SPSS software.

Associated publications:

Immunomodulators as therapeutic strategies for managing Multiple Sclerosis

Submitted: 01 12 2013

Available: 01 12 2013

Data time period: 2011

Click to explore relationships graph
Subjects

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Other Information
Identifiers